News | December 17, 2008

Boston Scientific Initiates Carotid Stent Clinical Study

December 18, 2008 - Boston Scientific Corp. today announced enrollment of the first patient in the CABANA post-market approval study of the company’s Carotid WALLSTENT Monorail Endoprosthesis used in conjunction with its FilterWire EZ Embolic Protection System.

The first patient was enrolled in the CABANA Study by Rajesh M. Dave, M.D., chairman, endovascular medicine, Pinnacle Health Heart and Vascular Institute, Harrisburg Hospital, Harrisburg, PA.

The CABANA Study is a multi-center, U.S. surveillance registry designed to enroll a minimum of 1,000 patients at up to 150 sites. The objective of the study is to compile early clinical outcomes data for the Carotid WALLSTENT Monorail Endoprosthesis and FilterWire EZ Embolic Protection System in routine clinical practice. The FDA approved the Carotid WALLSTENT in October. The FilterWire EZ Embolic Protection System received FDA clearance for use in carotid artery stenting procedures in December 2006.

“We are pleased to be part of this study, which follows recent FDA approval of the Carotid WALLSTENT with the use of the FilterWire EZ Embolic Protection System,” said Christopher J. White, M.D., chairman, department of cardiovascular diseases, Ochsner Clinic Foundation, New Orleans, and principal investigator of the study. “We expect that the user-friendly design and ease of use will contribute to improved outcomes in patients with carotid artery stenosis who are at increased risk for carotid surgery.”

The Carotid WALLSTENT Monorail Endoprosthesis is a self-expanding stent with a closed-cell design to promote increased scaffolding for excellent lesion coverage and a smooth inner lumen. It features a highly flexible, low-profile stent delivery system designed to provide exceptional tracking through difficult anatomy. The FilterWire EZ Embolic Protection System is designed to capture plaque debris that may be released during a procedure, preventing it from traveling to the brain, where it could cause a stroke. The Carotid WALLSTENT Endoprosthesis and Filter Wire EZ System is the only carotid artery stent system indicated in the United States for the treatment of certain patients at high risk for surgery with either ipsilateral or bilateral carotid artery disease (blockages in carotid arteries on one or both sides of the neck).

The BEACH Trial was a prospective, non-randomized, single-arm clinical trial with 480 patients, which demonstrated the safety and efficacy of the Carotid WALLSTENT Monorail Endoprosthesis and FilterWire EZ Embolic Protection System. These patients were considered high risk for carotid endarterectomy (CEA), the surgical treatment for carotid artery disease, because they had either anatomical issues (related to the anatomy of the neck, such as tight, tortuous vessels) or co-morbidity (multiple risk factors such as age, angina and heart failure). The primary endpoint in the BEACH trial was one-year morbidity and mortality defined as the cumulative incidence of non Q-wave myocardial infarction within 24 hours of the index procedure, peri-procedural (less than or equal to 30 days) death, stroke and Q-wave myocardial infarction and late ipsilateral stroke and neurological death from 31 days through 12-month follow-up. The one-year morbidity and mortality rate reported in the BEACH trial was 8.9 percent. The reported BEACH ipsilateral stroke rate (a stroke occurring on the treated side) was 3.3 percent, while the major ischemic stroke rate was 1.1 percent at 30 days.

For more information: www.bostonscientific.com

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Overlay Init